Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Autonomix Medical is a pre-revenue medical device company developing catheter-based sensing and ablation technologies for autonomic nervous system disorders. The company's lead product, the Autonomix System, targets conditions like pancreatic cancer pain and cardiovascular disorders through minimally invasive nerve modulation. With no commercial revenue, negative operating cash flow of approximately $10M annually, and an 87% stock decline over 12 months, the company is in clinical development stage facing significant execution and funding risks.
The business model targets a razor-razorblade approach where hospitals purchase the Autonomix System capital equipment (estimated $150K-250K per unit based on comparable interventional platforms), then generate recurring revenue from disposable catheters used in each procedure (estimated $3K-8K per procedure). The technology aims to address unmet needs in autonomic nerve mapping and ablation, competing against existing pain management approaches (opioids, surgical interventions) and emerging neuromodulation platforms. Pricing power depends on demonstrating superior clinical outcomes, procedural efficiency, and reimbursement coverage. Currently burning cash to fund clinical trials, regulatory submissions, and product development with no commercial traction.
Clinical trial data releases and FDA regulatory milestone announcements (IDE approvals, pivotal trial enrollment, breakthrough device designation)
Capital raises and financing announcements given negative cash flow and 6.18x current ratio suggesting 12-18 months runway
Partnership or licensing deals with larger medical device companies for commercialization or technology validation
Competitive developments in neuromodulation space (Boston Scientific, Medtronic nerve ablation platforms)
Physician adoption metrics and key opinion leader endorsements at medical conferences
FDA regulatory approval uncertainty for novel neuromodulation technology with limited predicate devices, requiring extensive clinical validation and potential multi-year PMA pathway
Reimbursement risk as payers may not cover novel autonomic nerve procedures without robust health economics data demonstrating cost-effectiveness versus existing pain management approaches
Technology obsolescence risk as larger competitors (Medtronic, Boston Scientific, Abbott) develop competing autonomic modulation platforms with superior resources and established hospital relationships
Well-capitalized competitors with established interventional platforms can rapidly develop similar autonomic sensing capabilities and leverage existing sales infrastructure for faster market penetration
Alternative pain management modalities including targeted drug delivery systems, spinal cord stimulation, and emerging gene therapies may address same patient populations with less invasive approaches
Physician adoption barriers as interventional radiologists and pain specialists have established workflows with existing technologies, requiring significant training investment and clinical evidence to switch
Severe liquidity risk with negative $10M+ annual operating cash flow and limited cash runway estimated at 12-18 months based on 6.18x current ratio, necessitating dilutive equity raises
Going concern risk given 87% stock decline, negative ROE of -228.8%, and no clear path to profitability without successful clinical trials and regulatory approvals 3-5 years away
Equity dilution risk as pre-revenue status requires continuous capital raises at depressed valuations, with 61% decline in recent 3 months suggesting deteriorating investor confidence and increasingly punitive financing terms
moderate - Pre-revenue medical device companies face indirect cyclical pressure. Economic downturns reduce risk appetite for speculative healthcare investments, tightening access to growth capital and increasing cost of equity financing. Hospital capital equipment budgets become constrained during recessions, potentially delaying future adoption even post-approval. However, the company's current stage (clinical development) is less sensitive to near-term economic conditions than commercial-stage peers. The addressable market for pain management and autonomic disorders remains relatively stable through cycles as these represent medical necessities rather than discretionary procedures.
Rising interest rates negatively impact pre-revenue biotech/medtech valuations through higher discount rates applied to distant future cash flows. The company's 0.4x price-to-book suggests significant market skepticism already priced in. Higher rates also increase financing costs for future capital raises and make risk-free alternatives more attractive to growth investors. With negative ROE of -228.8% and no debt currently (0.00 debt/equity), the company relies entirely on equity financing, making dilution more severe in high-rate environments. Each 100bps rate increase typically compresses early-stage medtech valuations by 15-25%.
Minimal direct credit exposure given zero debt and reliance on equity financing. However, tighter credit conditions indirectly impact the company by reducing venture capital and growth equity availability, forcing more dilutive financing terms. Hospital customers' access to capital equipment financing could affect future adoption rates post-commercialization. The company's 6.18x current ratio provides adequate liquidity buffer but requires monitoring as burn rate continues.
speculative growth - Attracts high-risk tolerance investors seeking asymmetric returns from binary clinical and regulatory outcomes. The 87% annual decline and pre-revenue status eliminate value and income investors. Typical shareholders include specialized healthcare venture funds, retail speculators, and momentum traders around catalyst events. The negative cash flow and dilution risk deter institutional quality growth investors until meaningful clinical validation occurs. Current 0.4x price-to-book suggests market assigns minimal probability to successful commercialization.
high - Pre-revenue medical device stocks exhibit extreme volatility around binary catalysts. The 61% quarterly decline demonstrates sensitivity to funding concerns and clinical timeline expectations. Typical beta exceeds 2.0x for similar pre-commercial medtech companies. Daily trading volumes likely thin, creating wide bid-ask spreads and susceptibility to momentum swings. Volatility will remain elevated until FDA approval clarity emerges or partnership de-risks commercialization path.
